IGF-1 LR3 VS IPA / CJC-1295
Both target the GH/IGF-1 axis but at different layers. IGF-1 LR3 is the modified IGF-1 analog that directly engages the IGF-1 receptor, bypassing the GH axis entirely. Ipamorelin + CJC-1295 are upstream secretagogues · they stimulate the pituitary to release endogenous GH, which drives hepatic IGF-1 production. Direct downstream vs upstream pulsatile.

Long R3 IGF-1 · extended half-life anabolic research compound

GH-Secretagogue Pair · Pulsatile
SIDE BY SIDE
WHICH IS BETTER · BY GOAL
Direct receptor engagement bypasses any rate-limiting steps in the GH-axis. Higher peak receptor occupancy per dose.
Ipa + CJC-1295 No DAC produces a GH pulse that approximates the natural diurnal pattern, which downstream IGF-1 inherits.
Selective ghrelin agonism (ipamorelin) avoids cortisol and prolactin elevation seen with older GHS. GHRH agonism (CJC-1295) acts upstream so endogenous feedback regulates total exposure.
STACKING NOTE
Not commonly stacked together in community protocols · they target the same axis at different layers. IGF-1 LR3 is typically used as a standalone direct-IGF-1R compound; Ipa/CJC-1295 as a pulsatile-GH-axis pair.
SOURCED FROM GIGACOMPOUNDS
Both compounds are available as research-grade material at GigaCompounds · ≥99% purity · per-batch CoA. For laboratory research use only.